the sun malaysia ipaper logo 150x150
Thursday, July 2, 2026
28.6 C
Kuala Lumpur
the sun malaysia ipaper logo 150x150

Property sales expected to rebound in 2H 2021 — Kenanga Research

KUALA LUMPUR: Property sales are expected to slow down in the first half of 2021 (1H 2021), but will see a mild rebound in 2H 2021, provided the Covid-19 situation improves, says Kenanga Research.

In a note today, it said the easing of lockdown restrictions is a positive sign as it will push the economic recovery onto the right track, but warns that a possible worsening of the Covid-19 situation may cause further setbacks.

As such, the research house has maintained its neutral call for property developers, in light of the sector’s challenging structural fundamentals of affordability, oversupply and policy issue.

Kenanga said the property overhang in Malaysia will remain and may not see marked improvement unless there is a meaningful correction in property prices in the near term to encourage demand.

“The property overhang situation is largely residential and serviced apartments, which make up 84 percent of the total overhang,” it said, adding that high-rise units account for 54 percent of the residential property overhang in Malaysia.

The research house believes that some developers may lower the pricing for certain product offerings in the near term to meet sales targets, as the market continues to target more affordable segments.

“Affordability will remain a major concern and we believe the government’s move to extend the Home Ownership Campaign and stamp duty exemption until 2025 — although positive — may not be sufficient to spur strong property demand,“ it added. — Bernama

STAY AHEAD OF THE CURVE

Join our community for instant updates and exclusive content.

Join Telegram Channel

Related


spot_img

Latest News

Bora Pharmaceuticals Completes Acquisition of MacroGenics’ Rockville Manufacturing Operations

TAIPEI, TAIWAN - Media OutReach Newswire - 2 July 2026 - Bora Pharmaceuticals Co., Ltd. ("Bora" or "Bora Group"; TWSE: 6472; OTCQX: BORAY) today announced the completion of its acquisition of the GMP manufacturing operations of MacroGenics, Inc. (NASDAQ: MGNX) including its biologics drug substance facility in Rockville, Maryland and an associated warehousing center in Frederick, Maryland, for total consideration of US $122.5 million through its wholly owned subsidiary Bora Biologics USA, LLC.. Upon closing, Bora signed a long-term CDMO Service Agreement with MacroGenics.

Most Viewed

spot_img
WC26

World Cup 2026

Updates, Fixtures, Results & Standings